JAK inhibitors in lichen planus: a review of pathogenesis and treatments

被引：28

作者：

Motamed-Sanaye, Ali ^{[1
,2
]}

Khazaee, Yasaman Fatemeh ^{[3
]}

Shokrgozar, Motahareh ^{[4
]}

Alishahi, Maryam ^{[4
]}

Ahramiyanpour, Najmeh ^{[5
]}

Amani, Maliheh ^{[6
]}

机构：

[1] Gonabad Univ Med Sci, Fac Med, Infect Dis Res Ctr, Student Res Comm, Gonabad, Iran

[2] Gonabad Univ Med Sci, Bohlool Hosp, Clin Res Dev Unit, Gonabad, Iran

[3] Gonabad Univ Med Sci, Fac Med, Dept Pediat, Gonabad, Iran

[4] Gonabad Univ Med Sci, Fac Med, Gonabad, Iran

[5] Kerman Univ Med Sci, Afzalipour Hosp, Afzalipour Fac Med, Dept Dermatol, Kerman, Iran

[6] Gonabad Univ Med Sci, Fac Med, Dept Dermatol, Gonabad, Iran

来源：

JOURNAL OF DERMATOLOGICAL TREATMENT | 2022年 / 33卷 / 08期

关键词：

Lichen planus; JAK inhibitors; JAK pathway; tofacitinib; barcitinib; upadacitinib; ruxolitinib; CELLS;

D O I：

10.1080/09546634.2022.2116926

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Lichen planus (LP) is an auto-inflammatory skin disorder identified by a presence of T-cell lymphocytes at the dermal-epidermal junction. It is hypothesized that the INF-gamma/CXCL10 axis fulfills a major role in the onset and persistence of chronic inflammation in LP. Since Janus kinases (JAKs) are involved in the transduction of INF-gamma signals, they may be good targets for LP treatment. Several case reports and case series described the safety and efficacy of upadacitinib (2 articles), tofacitinib (6 articles), baricitinib (4 articles), and Ruxolitinib (1 Article) in the treatment of LP variants. The predominant variants that JAK inhibitors improved were lichen planopilaris, nail LP, and erosive LP. Considering the role of the JAK pathway in LP pathogenesis and the evidence provided by these reports, it seems JAK inhibitors would be effective therapeutic agents for LP treatment. Hence, these agents should be trialed and evaluated further.

引用

页码：3098 / 3103

页数：6

共 32 条

[1] Treatment of Oral Erosive Lichen Planus With Upadacitinib
Balestri, Riccardo
Bortolotti, Roberto
Rech, Giulia
Girardelli, Carlo Rene
Zorzi, Maria Grazia
Magnano, Michela
[J]. JAMA DERMATOLOGY, 2022, 158 (04) : 457 - 458
[2] Bilgili SG, 2012, J PAK MED ASSOC, V62, P535
[3] Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis
Boy, Mary G.
Wang, Cunshan
Wilkinson, Bethanie E.
Chow, Vincent Fung-Sing
Clucas, Alan T.
Krueger, James G.
Gaweco, Anderson S.
Zwillich, Samuel H.
Changelian, Paul S.
Chan, Gary
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 (09) : 2299 - 2302
[4] Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus: A Prospective, Open-Label Study
Brumfiel, Caitlin M.
Patel, Meera H.
Severson, Kevin J.
Zhang, Nan
Li, Xing
Quillen, Jaxon K.
Zunich, Samantha M.
Branch, Emily L.
Nelson, Steven A.
Pittelkow, Mark R.
Mangold, Aaron R.
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : 2109 - +
[5] Treatment of severe lichen planus with the JAK inhibitor tofacitinib
Damsky, William
Wang, Alice
Olamiju, Brianna
Peterson, Danielle
Galan, Anjela
King, Brett
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (06) : 1708 - +
[6] Targeting the IFN-γ/CXCL10 pathway in lichen planus
Di Lernia, Vito
[J]. MEDICAL HYPOTHESES, 2016, 92 : 60 - 61
[7] Upadacitinib: First Approval
Duggan, Sean
Keam, Susan J.
[J]. DRUGS, 2019, 79 (16) : 1819 - 1828
[8] Jakpot! New small molecules in autoimmune and inflammatory diseases
Ghoreschi, Kamran
Gadina, Massimo
[J]. EXPERIMENTAL DERMATOLOGY, 2014, 23 (01) : 7 - 11
[9] Tofacitinib as Treatment for Nail Lichen Planus Associated With Alopecia Universalis
Iorizzo, Matilde
Haneke, Eckart
[J]. JAMA DERMATOLOGY, 2021, 157 (03) : 352 - 353
[10] Semaphorin4D Drives CD8+ T-Cell Lesional Trafficking in Oral Lichen Planus via CXCL9/CXCL10 Upregulations in Oral Keratinocytes
Ke, Yao
Dang, Erle
Shen, Shengxian
Zhang, Tongmei
Qiao, Hongjiang
Chang, Yuqian
Liu, Qing
Wang, Gang
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (11) : 2396 - 2406

← 1 2 3 4 →